Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program

The Cancer Immunotherapy Immunoguiding Program has conducted an IFN-γ ELISPOT proficiency panel to examine the influence of serum supplementation of test media on assay performance. Sixteen European laboratories analyzed the same PBMC samples using different locally established protocols. Participants generated two simultaneous data sets—one using medium supplemented with serum and one without serum. Performances of the two test conditions were compared by quantifying: (1) the number of viable cells, (2) background spot formation induced in the medium only control and (3) the ability to detect antigen-specific T cell responses. The study demonstrated that the number of viable cells recovered and the overall background spot production were not significantly different between the two conditions. Furthermore, overall laboratory performance was equivalent for the two test conditions; 11 out of 16 laboratories reported equal or greater detection rates using serum-free medium, while 5 laboratories reported decreased detections rates under serum-free conditions. These results show that good performance of the IFN-γ ELISPOT assay can be achieved under serum-free conditions. Optimization of the protocol for serum-free conditions should result in excellent detection rates and eliminate the requirement of serum batch and stability testing, allowing further harmonization of the assay.

[1]  P. Defechereux,et al.  Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization , 2009, Clinical and Vaccine Immunology.

[2]  Sylvia Janetzki,et al.  "MIATA"-minimal information about T cell assays. , 2009, Immunity.

[3]  Sylvia Janetzki,et al.  Standardization and validation issues of the ELISPOT assay. , 2005, Methods in molecular biology.

[4]  A. Mackensen,et al.  The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.

[5]  G. Karthikeyan,et al.  Progressive degradation of serum samples limits proteomic biomarker discovery. , 2009, Analytical biochemistry.

[6]  R. Powell.  Clinical Immunology , 1976, The Lancet.

[7]  A. Eggermont,et al.  A clinical development paradigm for cancer vaccines and related biologics. , 2007, Journal of immunotherapy.

[8]  Ferdousi Chowdhury,et al.  Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines , 2009, Cancer Immunology, Immunotherapy.

[9]  H. Dockrell,et al.  Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations , 2008, PLoS medicine.

[10]  Lars Mørkrid,et al.  Long‐term stability of serum components in the Janus Serum Bank , 2008, Scandinavian journal of clinical and laboratory investigation.

[11]  Sjoerd H van der Burg,et al.  Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding , 2008, Expert review of vaccines.

[12]  Holden T Maecker,et al.  Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides , 2008, BMC Immunology.

[13]  K. Silina,et al.  ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring—even in hands of ELISPOT-inexperienced investigators , 2009, Journal of immunotoxicology.

[14]  Guido Ferrari,et al.  Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. , 2005, AIDS research and human retroviruses.

[15]  M. Caulfield,et al.  Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions , 2007, Clinical and Vaccine Immunology.

[16]  C. Gouttefangeas,et al.  Toward the harmonization of immune monitoring in clinical trials: Quo vadis? , 2007, Cancer Immunology, Immunotherapy.

[17]  P. van Endert,et al.  Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection. , 2008, Journal of immunological methods.

[18]  A. Dalgleish,et al.  Improving the efficacy of cancer immunotherapy. , 2009, European journal of cancer.

[19]  P. Elliott,et al.  The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. , 2008, International journal of epidemiology.

[20]  L. Ben-Porat,et al.  Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium , 2009, Cancer Immunology, Immunotherapy.

[21]  Bjoern Peters,et al.  HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.

[22]  Sylvia Janetzki,et al.  Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) , 2007, Cancer Immunology, Immunotherapy.

[23]  Yingdong Zhao,et al.  A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" , 2008, Journal of Translational Medicine.

[24]  S. H. van der Burg,et al.  Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells , 2009, Cancer Immunology, Immunotherapy.

[25]  L. J. Old,et al.  Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond , 2010, Cancer Immunology, Immunotherapy.

[26]  J. Bartůňková,et al.  Department of Immunology , 2009 .